Usually trial courts are the exclusive finders of facts and appellate courts are limited to questions of law, but apparently that’s not necessarily the case when it comes to patent law. In a dispute between Teva Pharmaceuticals, which holds the patent on the very profitable multiple sclerosis drug Copaxone, and companies that want to begin marketing a generic version the trial court sided with Teva. The U.S. Court of Appeals for the Federal Circuit, which reviews patent cases, however, looks at all elements of a patent claim as legal issues, including the factual conclusions of the trial court and reversed.
Even though Teva’s patent expires in September of next year the amount of money at stake is huge – in the billions. Also at stake is a shift of power from the Federal Circuit.
The case is Teva Pharmaceuticals v. Sandoz
Here are my sketches and a link to Lyle’s SCOTUSblog analysis of the argument.